ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00130936
Recruitment Status : Terminated
First Posted : August 17, 2005
Last Update Posted : February 15, 2016
Sponsor:
Information provided by:
AHS Cancer Control Alberta

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Terminated
  Primary Completion Date : No date given
  Actual Study Completion Date : November 2007